Information Provided By:
Fly News Breaks for March 23, 2015
SGEN
Mar 23, 2015 | 08:22 EDT
RBC Capital believes that the Lancet editorial on Seattle Genetics' AETHERA was positive, and the firm expects the drug's label to expand. However, the firm warns that for further upside Seattle Genetics needs one or more programs targeting unmet need with clearly delineated paths to approval. The firm keeps a $50 price target and Outperform rating on the shares.
News For SGEN From the Last 2 Days
There are no results for your query SGEN